Tonni Gabriele, Palicelli Andrea, Bassi Maria Chiara, Torricelli Federica, Vacca Ilaria, Aguzzoli Lorenzo, Mandato Vincenzo Dario
Department of Obstetrics and Neonatology, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS), Azienda USL-IRCCS di Reggio Emilia, Via Amendola 2, 42123 Reggio Emilia, Italy.
Pathology Unit, Azienda USL-IRCCS di Reggio Emilia, 42123 Reggio Emilia, Italy.
Cancers (Basel). 2024 Jun 23;16(13):2305. doi: 10.3390/cancers16132305.
Gastrointestinal stromal tumors (GISTs) are a rare neoplasm, sometimes mimicking primary ovarian tumors (OTs) and/or metastasizing to the ovaries (M-OT). We performed a systematic literature review (SLR) of OTs and M-OTs, investigating differences in recurrence-free and overall survival. Our SLR was performed according to PRISMA guidelines, searching in Pubmed, Scopus, and Web of Science databases from inception until 21 April 2024. Overall, 59 OTs (Group 1) and 21 M-OTs (Group 2) were retrieved. The absence of residual disease after surgery was achieved significantly in a higher percentage of patients with Group 1 GISTs (91.5%) compared with Group 2 GISTs (57.1%). Chemotherapy was more frequently administered to Group 2 patients (33% vs. 0%). Recurrence and deaths for disease were significantly more frequent in Group 2 than Group 1 cases (54.5% vs. 6.8%, and 37.5% vs. 9.8%, respectively). GISTs can rarely mimic primary ovarian cancers or even more rarely metastasize to the ovaries. Group 1 GISTs occurred in younger women, were not associated with elevated tumor markers, and had a better prognosis. In contrast, Group 2 GISTs occurred in older women, may exhibit elevated tumor markers, and presented a worse prognosis. However, no significant statistical difference for survival between the two studied groups was detected. Computed tomography scans can define the size of GISTs, which correlate to stage and prognostic risk classes. The gold standard treatment is complete surgical resection, which was achieved in almost all cases of Group 1 GISTs and in half of Group 2. Histopathology and immunohistochemistry are essential for the final diagnosis and guide chemotherapy treatment.
胃肠道间质瘤（GISTs）是一种罕见的肿瘤，有时会模仿原发性卵巢肿瘤（OTs）和/或转移至卵巢（M-OT）。我们对OTs和M-OTs进行了系统的文献综述（SLR），研究无复发生存期和总生存期的差异。我们的SLR按照PRISMA指南进行，在PubMed、Scopus和Web of Science数据库中从创建到2024年4月21日进行检索。总体而言，检索到59例OTs（第1组）和21例M-OTs（第2组）。与第2组GISTs（57.1%）相比，第1组GISTs患者术后无残留疾病的比例显著更高（91.5%）。第2组患者接受化疗的频率更高（33%对0%）。第2组疾病复发和死亡的频率显著高于第1组病例（分别为54.5%对6.8%，37.5%对9.8%）。GISTs很少能模仿原发性卵巢癌，甚至更罕见地转移至卵巢。第1组GISTs发生在年轻女性中，与肿瘤标志物升高无关，预后较好。相比之下，第2组GISTs发生在老年女性中，可能表现出肿瘤标志物升高，预后较差。然而，在两个研究组之间未检测到生存的显著统计学差异。计算机断层扫描可以确定GISTs的大小，其与分期和预后风险类别相关。金标准治疗是完整的手术切除，在几乎所有第1组GISTs病例和第2组的一半病例中都实现了。组织病理学和免疫组织化学对于最终诊断和指导化疗治疗至关重要。
